The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaBradley A. McGregor, Joaquim Bellmunt, Guru Sonpavde et al.|Annals of Oncology|2023Cited by 94
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate CancerJamie M. Sperger, Joshua M. Lang, Hamid Emamekhoo et al.|Journal of Clinical Oncology|2021Cited by 62
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R. McKay, Mary‐Ellen Taplin, Lucia Kwak et al.|Clinical Cancer Research|2021Cited by 32
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.Bradley A. McGregor, Guru Sonpavde, Joaquim Bellmunt et al.|Journal of Clinical Oncology|2022Cited by 7
2360O The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)Bradley A. McGregor, Joaquim Bellmunt, Guru Sonpavde et al.|Annals of Oncology|2023Cited by 4